Diclofenac Extended-Release Tablets bulk supplier for pharma manufacturers

Diclofenac Extended-Release Tablets 100 mg Suppliers & Bulk Manufacturers

Available Forms: Extended-Release Tablets

Available Strengths: 100 mg

Reference Brands: Voltaren(US & EU), Voveran SR (India)

Category: Arthritis

Diclofenac ER tablets inhibit cyclooxygenase enzymes (COX-1 and COX-2), reducing prostaglandin synthesis, which alleviates pain and inflammation. The extended-release formulation provides long-lasting relief, decreases dosing frequency, and improves compliance. Benefits include effective management of chronic pain, arthritis, and inflammatory conditions with sustained, predictable symptom control.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Diclofenac ER (Extended-Release) tablets are approved in the EU and US for managing chronic pain and inflammation. In the EU, brands like Voltaren ER are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and quality. In the US, FDA approval is based on comprehensive clinical data and biosimilarity assessments, with generic versions available. Both regions require detailed dossiers for approval and ongoing pharmacovigilance. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We help facilitate efficient market access for diclofenac ER tablets, ensuring adherence to European and American standards for safe, effective long-term anti-inflammatory therapy.

Diclofenac Extended-Release Tablets — third party manufacturing & bulk supply

Diclofenac Extended-Release Tablets 100 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Diclofenac Extended-Release Tablets is supplied as Extended-Release Tablets — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Diclofenac Extended-Release Tablets listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Diclofenac Extended-Release Tablets →

Back to Listing

Frequently Asked Questions

Diclofenac Extended-Release is used to relieve pain, reduce inflammation, and manage symptoms of conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and other musculoskeletal disorders. Its extended-release formulation allows for longer-lasting effects and reduced dosing frequency.

Diclofenac Extended-Release contains diclofenac sodium, a non-steroidal anti-inflammatory drug (NSAID). It works by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes, which reduces the production of prostaglandins responsible for pain, inflammation, and fever.

Common trade names include Voltaren XR, Voltarol Retard, Voveran SR, Diclo SR, and Voltaren SR.

Diclofenac Extended-Release is manufactured by multiple pharmaceutical companies worldwide. Major brands are produced by Novartis, Cipla Ltd., and other generic manufacturers.

The generic name is Diclofenac sodium.

Common brand names include Voltaren XR, Voltarol Retard, Voveran SR, Diclo SR, and Voltaren SR.

Diclofenac Extended-Release is manufactured in GMP-certified pharmaceutical facilities in countries such as India, Switzerland, the United States, and other global manufacturing hubs by both innovator and generic pharmaceutical companies.